The Protective Role of HLA-DRB113 in Autoimmune Diseases

Table 2

Associations between HLA class II and six AIDs: SLE, Ps + PsA, RA, SSc, MS, and MG.

	Controls; ()	SLE; ()	Ps + PsA; ()	RA; ()	SSc; ()	MS; ()	MG; ()	Total; ()
HLA-DRB101	66 (23.4%)	40 (18.8%)	39 (23.5%)	50 (32.7%); OR = 1.79; p = 0.017	28 (41.8%); OR = 2.28; p = 0.006	100 (18.7%)	23 (24.7%)	280 (22.8%)
HLA-DRB103	44 (15.6%)	73 (34.3%); OR = 2.49; p = 4.2 × 10^−5	25 (15.1%)	28 (18.3%)	11 (16.4%)	123 (22.9%); OR = 1.81; p = 0.003	33 (35.5%); OR = 2.98; p = 6.1 × 10^−5	293 (23.9%); OR = 1.51; p = 0.022
HLA-DRB104	69 (24.5%)	42 (19.7%)	46 (27.7%)	73 (47.7%); OR = 2.81; p = 6 × 10^−6	13 (19.4%)	128 (23.9%)	23 (24.7%)	325 (26.5%)
HLA-DRB107	72 (25.5%)	55 (25.8%)	66 (39.8%); OR = 1.79; p = 0.006	38 (24.8%)	14 (20.9%)	147 (27.4%)	23 (24.7%)	343 (27.9%)
HLA-DRB108	24 (8.5%)	21 (10.0%)	10 (6.0%)	3 (2.0%); OR = 0.24; p = 0.026	15 (22.4%); OR = 3.01; p = 0.004	65 (12.1%); OR = 1.73; p = 0.033	7 (7.5%)	121 (9.9%)
HLA-DRB109	14 (5.0%)	2 (1.0%); OR = 0.18; p = 0.027	5 (3.0%)	0 (0.0%); OR = 0.95; p = 0.003	3 (4.5%)	5 (1.0%); OR = 0.22; p = 0.004	2 (2.2%)	17 (1.4%); OR = 0.23; p = 1 × 10^−4
HLA-DRB113	84 (29.8%)	39 (18.3%); OR = 0.58; p = 0.016	32 (19.3%); OR = 0.62; p = 0.050	25 (16.3%); OR = 0.58; p = 0.044	8 (11.9%); OR = 0.42; p = 0.035	124 (23.1%)	17 (18.3%)	245 (20.0%); OR = 0.58; p = 0.004
HLA-DRB115	56 (19.9%)	55 (25.8%)	22 (13.3%)	17 (11.1%)	12 (17.9%)	175 (32.7%); OR = 2.17; p = 2 × 10^−5	15 (16.1%)	296 (24.1%)

AIDs: autoimmune diseases; SLE: Systemic Lupus Erythematosus; Ps + PsA: Psoriasis or Psoriatic Arthritis; RA: Rheumatoid Arthritis; SSc: Systemic Sclerosis; MS: Multiple Sclerosis; MG: Myasthenia Gravis. Fisher’s exact test was used to calculate this value.